Waiting is the hardest part

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3781-3782

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPRATUZUMAB; EVEROLIMUS; FOSTAMATINIB; GALIXIMAB; IBRUTINIB; IDELALISIB; LENALIDOMIDE; RITUXIMAB;

CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE; WATCHFUL WAITING;

FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; WATCHFUL WAITING;

EID: 84869228595     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6584     Document Type: Editorial

References (21)

1. Poe EA: The pit and the pendulum, in The Gift: A Christmas and New Year's Present for 1843. Philadelphia, PA, Carey and Hart, 1843 pp 133-151
2. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984 (Pubitemid 15211022)
3. Brice P, Bastion Y, Lepage E, et al: Comparison of low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Group d'Etude des Lymphomes Folliculares. J Clin Oncol 15:1110-1117, 1997 (Pubitemid 27106296)
4. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003 (Pubitemid 36976715)
5. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
6. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
7. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
8. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
9. Ardeshna KM, Qian W, Smith P, et al: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): A preliminary analysis. Blood 116:5, 2010 (abstr 6)
10. Sinha R, Byrtek M, DeJoubner NJ, et al: Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Blood 118:351, 2011 (abstr 775)
11. Solal-Céligny P, Bellei M, Marcheselli L, et al: Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database. J Clin Oncol 30:3848-3853, 2012
12. Federico M, Bellei M, Marcheselli L, et al: Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555-4562, 2009
13. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
14. Czuczman MS, Leonard JP, Jung S, et al: Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol [epub ahead of print on February 22, 2012]
15. Grant BW, Leonard JP, Johnson JL, et al: Combination biologic therapy as initial treatment for follicular lymphoma: Initial results from CALGB 50701 - A phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood 116:191, 2010 (abstr 427)
16. Fowler N, Hagemeister F, McLaughlin P, et al: Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin's lymphoma. Ann Oncol 22:128-129, 2011 (abstr 137)
17. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585, 2010
18. Fowler N, Sharman JP, Smith SM, et al: The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood 116:425, 2010 (abstr 964)
19. Kahl B, Byrd JC, Flinn IW, et al: Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 116:741, 2010 (abstr 1777)
20. Witzig TE, Reeder CB, LaPlant BR, et al: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25:341-347, 2011
21. Witzig TE, Wiernik PH, Moore T, et al: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 27:5404-5409, 2009